LaPlace
50 Raffles Place #22-01 Singapore Land Tower, Singapore, 048623
Overview
Laplace is the world's first client-centric digital investment bank, offering institutional-grade tokenized assets including private securities & equities, real-world assets, and money market instruments like US Treasuries. Our crypto high-frequency trading platform empowers investors with advanced risk management and maximized return opportunities.
- Total investments
- 1
- Lead investments
- 0
- Investments · 12mo
- 0
- Active investors
- 0
Sector focus
- Blockchain
- Cryptocurrency
- Decentralized Finance (DeFi)
- Finance
- Financial Services
- FinTech
- Infrastructure
- Trading Platform
Investment portfolio
- Ingenium Therapeutics
Participated · Series A · Apr 2022
Founded in 2020, Ingenium Therapeutics is building a next-generation anti-cancer platform that mass-produces memory Natural Killer (NK) cells capable of both tumor-killing and immune-modulating activity. Its lead candidate, Genglueucel (IGNK001), received an International Non-proprietary Name (INN) from the WHO in 2023 and has been granted FDA Orphan Drug Designation, allowing it to skip Phase 1 and move directly into Phase 2 trials. The company is currently preparing a Phase 2 IND at the world’s largest cancer center. Ingenium’s proprietary manufacturing process can generate large quantities of memory NK cells, giving it a commercialization advantage. The firm plans to use upcoming funding to advance global clinical studies and pursue out-licensing discussions with multinational pharmaceutical companies. Cumulatively, the company has raised more than ₩16 billion and is targeting an IPO in 2028 with Kiwoom Securities as lead underwriter.
Team
No current team members are available.